The syndicated ChartTrends: Multiple Sclerosis (US) report allows clients to better understand the actual treatment of multiple sclerosis (MS) with disease-modifying therapies (DMTs) through comparison of what physicians self-report about disease management to what occurs at the patient level. Through an in-depth review of charts from patients currently treated with Aubagio, Avonex, Betaseron, Copaxone, Gilenya, Rebif, Tecfidera, and Tysabri, details such as product initiation, switching, monitoring, and a host of tests and patient demographic variables help define patient types and identify drivers of therapy choice. The report also evaluates physician receptivity to products in development for the treatment of MS, and identifies potential characteristics of patient candidates for each product.
Questions Answered in This Report:
What are the demographics/treatment history of patients treated with DMTs, including diagnosis, MS symptoms, comorbidities, exacerbations, and disease progression? How are MRI and laboratory assessments used in the monitoring of MS patients?
What is the treatment paradigm for the chronic management of MS? What is the paradigm for the management of exacerbations and MS-related symptoms?
How frequently are patients tested with the anti-JC virus antibody assay? What factors drive the decision to test patients with the anti-JC virus antibody assay? How do test results impact prescribing behavior?
What factors drive the decision to initiate DMT treatment in treatment-naïve patients? What drives the selection of current DMT brands? What drives the discontinuation of therapy?
What is a typical patient profile for each of the individual DMT brands?
How receptive are physicians to products in development for MS? What are some identifying characteristics of potential candidates for these products?
- ~200 fellowship-trained neurologists complete an online quantitative survey plus patient audits for between four to seven of their MS patients
To qualify, respondents must meet the following criteria:
- Minimum of 20 patients with relapsing-remitting MS under management
- Have been in practice a minimum of 2 years and a maximum of 35 years
- More than 75% of professional time spent in clinical practice
Each patient record meets the following criteria:
- At least 18 years of age
- Be treated with a DMT for at least the past six months
- Final report in PowerPoint format
- Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request
- Database containing de-identified patient audit data in SPSS and/or
Excel available upon request
- United States
Key Drugs Covered:
- Aubagio (teriflunomide), Avonex (interferon-beta-1a intramuscular), Betaseron (interferon-beta-1b), Co-paxone (glatiramer acetate), Extavia (interferon-beta-1b), Gilenya (fingolimod), Rebif (interferon-beta-1a subcutaneous), Tecfidera (dimethyl fumarate), Tysabri (natalizumab), Lemtrada (alemtuzumab), Plegridy (pegylated interferon-beta-1a subcu-taneous), Nerventra (laquinimod), daclizumab, ocrelizumab
Key Companies Mentioned:
- AbbVie, Active Biotech, Bayer, Bio-gen Idec, EMD Serono (a Merck KGaA company), Genentech, Gen-zyme (a Sanofi company), Novartis, Pfizer, Roche, Teva
TreatmentTrends®: Multiple Sclerosis (US) 2014
TreatmentTrends®: Multiple Sclerosis (EU) 2013
LaunchTrends®: Aubagio (US) 2013
LaunchTrends®: Tecfidera (US) 2014
LaunchTrends®: Lemtrada (US) TBD
DecisionBase®: Multiple Sclerosis-Relapsing Remitting 2014
DecisionBase®: Multiple Sclerosis-Chronic Progressive 2014
Pharmacor®: Multiple Sclerosis 2014
Treatment Algorithms®: Multiple Sclerosis 2014
Physician and Payer Forum®: Multiple Sclerosis (US) 2014
Physician and Payer Forum®: Multiple Sclerosis (EU) 2014
PatientBase®: Multiple Sclerosis in G7 2014